戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 vs deferoxamine (P = .057 for superiority of deferasirox).
2 g that this signaling pathway is targeted by Deferasirox.
3 ) for deferiprone and 381 days (350-392) for deferasirox.
4 zation more than additive (synergistic) with deferasirox.
5 effect to piroctone, 8-hydroxyquinoline, and deferasirox.
6 ow the non-inferiority of deferiprone versus deferasirox.
7 hs, none of which were considered related to deferasirox.
8 edications desferrioxamine, deferiprone, and deferasirox.
9                                           Fe(deferasirox)(2) displays an outstanding thermodynamic st
10  3 T MRI scanner, the contrast ability of Fe(deferasirox)(2) is comparable to the one shown by the co
11                      The binding sites of Fe(deferasirox)(2) on albumin were characterized by relaxom
12 dministered with a dose of 0.1 mmol/kg of Fe(deferasirox)(2) showed that the complex is completely re
13  deferiprone (75-100 mg/kg per day) or daily deferasirox (20-40 mg/kg per day) administered as disper
14 elated adverse events was comparable between deferasirox (35.4%) and deferoxamine (30.8%).
15 h placebo by LSM -235 and -337 ng/mL for the deferasirox 5 and 10 mg/kg/d groups, respectively (P < .
16 oordinated Fe(III) complex with two units of deferasirox, a largely used iron sequestering agent, own
17 xamined the in vitro and in vivo activity of deferasirox against cells from human solid tumors.
18                     Here we demonstrate that deferasirox, an iron chelator recently approved for use
19 rs, namely, desferrioxamine, deferiprone and deferasirox and compared them with experimental agent sa
20                                              Deferasirox and deferiprone are the only two oral chelat
21                         Two new oral agents, deferasirox and deferiprone, have become available in th
22 ssaemia, aged 2-15 years, who were receiving deferasirox and had available baseline and follow-up ser
23        The increased AKI risk with high-dose deferasirox and lower serum ferritin concentration is co
24 sed in patients receiving different doses of deferasirox and the comparator deferoxamine.
25 udy following a single 35-mg/kg dose of oral deferasirox; and pharmacogenomic analysis.
26 ic iron imaging and the availability of oral deferasirox are expected to improve clinical care, but t
27 rculosis, malaria), broader investigation of deferasirox as an antiinfective treatment is warranted.
28 on the safety and efficacy results, starting deferasirox at 10 mg/kg/day appears to be most appropria
29  randomized clinical trial demonstrates that deferasirox at 20 to 30 mg/kg/d can maintain or improve
30 ed 30% sickle hemoglobin (HbS) and tolerated deferasirox at 28.2 +/- 6.0 mg/kg/d.
31 ots are consistent with ELT donating iron to deferasirox at clinically relevant concentrations.
32 tained with deferiprone, desferrioxamine, or deferasirox at similar iron-binding equivalents.
33 T scavenges iron citrate species faster than deferasirox, but rapidly donates the chelated iron to de
34 l decreases in eGFR correlate with increased deferasirox C(min), especially in younger patients.
35                                              Deferasirox can cause AKI in a dose-dependent manner.
36  CORDELIA demonstrated the noninferiority of deferasirox compared with deferoxamine for myocardial ir
37 y to characterize the safety and efficacy of deferasirox, comprising a core and an extension phase (e
38 ox, but rapidly donates the chelated iron to deferasirox, consistent with a shuttling mechanism.
39                                              Deferasirox demonstrated similar activity at inhibiting
40   In this work, we report the use of several deferasirox derivatives as lanthanide chelators.
41                                              Deferasirox (DFX) monotherapy is effective for reducing
42 , deferoxamine (DFO), deferiprone (DFP), and deferasirox (DFX), including their efficacy, patient acc
43 esented by Pennell and colleagues shows that deferasirox (DFX; Exjade, Novartis) is not inferior to d
44 ine and 1 year vs 80 [54.8%] of 146 assigned deferasirox, difference 0.4%; 95% CI -11.9 to 12.6).
45 was observed per 5 mg/kg per day increase in deferasirox dispersible tablet dose (equivalent to a 3.5
46                                    High-dose deferasirox (dispersible tablet dose >30 mg/kg per day)
47 is study aimed to investigate the effects of deferasirox dose and serum ferritin concentrations on ki
48                                         At a deferasirox dose of 20 mg/kg per day, neutral or negativ
49  In the cardiac iron reduction arm, the mean deferasirox dose was 32.6 mg/kg per day.
50 ising ferritin trend or rising liver iron on deferasirox doses > 30 mg/kg per day) with control trans
51              All patients initially received deferasirox doses of 30 to 40 mg/kg per day.
52 patients were enrolled and received starting deferasirox doses of 5 (n = 11), 10 (n = 15), or 15 (n =
53                                              Deferasirox doses of 5, 10, and 15 mg/kg/day can reduce
54               The means +/- SD of the actual deferasirox doses received over the duration of the stud
55                                              Deferasirox effectively chelated iron from Rhizopus oryz
56          The once-daily, oral iron chelator, deferasirox (Exjade) may provide an alternative treatmen
57   The predominant chelator currently used is deferasirox, followed by deferoxamine and then combinati
58                              After receiving deferasirox for 48 weeks, median serum ferritin levels d
59 omparison data on the efficacy and safety of deferasirox for myocardial iron removal in transfusion d
60 jective was to demonstrate noninferiority of deferasirox for myocardial iron removal, assessed by cha
61 ic mean (Gmean) myocardial T2* improved with deferasirox from 11.2 milliseconds at baseline to 12.6 m
62 up (194 to the deferiprone group; 199 to the deferasirox group).
63 of each) occurred in the 197 patients in the deferasirox group.
64  Fe/g dw, P < .001) for the 5 and 10 mg/kg/d deferasirox groups, respectively (baseline values [means
65         Patients with inadequate response to deferasirox had significantly lower systemic drug exposu
66                       The oral iron chelator deferasirox has become commercially available in many co
67 inoyl hydrazone (311), and the iron chelator deferasirox (ICL670) inhibits HIV-1 transcription.
68 a) trial assessed the efficacy and safety of deferasirox in iron-overloaded NTDT patients.
69 er trial assessed the safety and efficacy of deferasirox in low- or intermediate-1-risk myelodysplast
70 iprone, a less expensive iron chelator, with deferasirox in paediatric patients.
71                              The efficacy of deferasirox in reducing or preventing cardiac iron overl
72 o show non-inferiority of deferiprone versus deferasirox in the per-protocol population, defined as a
73 ed trial of oral iron chelation therapy with deferasirox in this population.
74 sing data from the 1-year phase III study of deferasirox, including volumes of transfused red blood c
75                         We demonstrated that deferasirox increased expression of the metastasis suppr
76                            Serious and fatal deferasirox-induced kidney injury has been reported in p
77 ent received monthly transfusions plus daily deferasirox iron chelation.
78                                              Deferasirox is an FDA-approved iron chelator used in the
79            Collectively, we demonstrate that deferasirox is an orally effective antitumor agent again
80                                              Deferasirox is an orally effective iron (Fe) chelator cu
81            This prospective study shows that deferasirox is effective in removing and preventing myoc
82  per day) or deferasirox (<40 mg/kg per day; deferasirox is not registered for use in children aged <
83 ceiving deferoxamine (<100 mg/kg per day) or deferasirox (&lt;40 mg/kg per day; deferasirox is not regis
84  impaired kidney function on dose-normalised deferasirox minimum plasma concentration (C(min)).
85 mens for inadequately responding patients to deferasirox must be determined.
86 been no studies to investigate the effect of deferasirox on these types of tumors in vivo.
87 djustment, reductions in LIC after 1 year of deferasirox or deferoxamine therapy correlated with tran
88 red upon administration of the iron chelator deferasirox or hyperexpression of Fpn1 or Nrf2.
89 atio to starting doses of 5 or 10 mg/kg/d of deferasirox or placebo.
90 tions include combination lipid polyene plus deferasirox or posaconazole therapy.
91 ne of the three iron chelators (deferiprone, deferasirox, or deferoxamine).
92     We performed a prospective study of oral deferasirox pharmacokinetics (PK), comparing 10 transfus
93 c uptake and excretion of chelate; a 24-hour deferasirox PK study following a single 35-mg/kg dose of
94                                     However, deferasirox potently inhibited DMS-53 xenograft growth i
95                                              Deferasirox reduces serum ferritin and LPI in transfusio
96 aring 10 transfused patients with inadequate deferasirox response (rising ferritin trend or rising li
97 3) and cells from MDS patients refractory to Deferasirox showed a specific increase of ROS and PI-PLC
98 hematopoietic cells treated with FeCl(3) and Deferasirox, showed a specific reduction of PI-PLCbeta1/
99 dotic or neutropenic mice with mucormycosis, deferasirox significantly improved survival and decrease
100  induced by treatment with the iron chelator deferasirox significantly protected flies infected with
101 unachievable concentrations, deferiprone and deferasirox significantly reduced the catecholamine neur
102 mized study showing that iron chelation with deferasirox significantly reduces iron overload in NTDT
103                            Most importantly, deferasirox synergistically improved survival and reduce
104  was a prospective, randomized comparison of deferasirox (target dose 40 mg/kg per day) vs subcutaneo
105 uating response of cardiac and liver iron to deferasirox therapy for 18 months.
106 ed the molecular features of iron effect and Deferasirox therapy on PI-PLCbeta1 inositide signaling,
107 support clinical investigation of adjunctive deferasirox therapy to improve the poor outcomes of muco
108 we treated the patient with off-label use of deferasirox to maintain iron deficiency, with successful
109                                   Among 1213 deferasirox-treated paediatric patients, 162 cases of AK
110                                              Deferasirox treatment also enhanced the host inflammator
111 n acceptable body iron burden, and interrupt deferasirox treatment when AKI or volume depletion are s
112 s deferoxamine alone, and the equivalence of deferasirox versus deferoxamine.
113 argin of 0.9, establishing noninferiority of deferasirox vs deferoxamine (P = .057 for superiority of
114                         The starting dose of deferasirox was 20 mg/kg/d, with dose escalation up to 4
115                             Monotherapy with deferasirox was effective in patients with mild to moder
116        Non-inferiority of deferiprone versus deferasirox was established (treatment success in 69 [55
117                                 Furthermore, deferasirox was generally similar or slightly more effec
118                      The novel oral chelator deferasirox was recently approved by the Food and Drug A
119                                              Deferasirox was shown to reduce iron overload in patient
120      To understand the antitumor activity of deferasirox, we investigated its effect on the expressio
121 ne (CPX), piroctone, 8-hydroxyquinoline, and deferasirox-were also shown to efficiently chelate intra

 
Page Top